Wenfeng Fang
Wenfeng Fang is a lung cancer oncologist at the centre of China's PD-1 and bispecific antibody trials, including ivonescimab in EGFR-mutant disease.
Wenfeng Fang has led or co-led trials of camrelizumab, ivonescimab (HARMONi-A), and other immunotherapies in NSCLC and nasopharyngeal carcinoma at SYSUCC.
Pages like this
not linked directly; found by shared links- TrialHARMONi-2
Shares Ivonescimab, VEGF / VEGFR, PD-1, Non-small-cell lung cancer.
- PersonCaicun Zhou
Shares Akeso, Ivonescimab, VEGF / VEGFR, PD-1.
- PersonLi Zhang
Shares Camrelizumab, Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- TrialJUPITER-02
Shares Sun Yat-sen University Cancer Center, PD-1, Head and neck squamous cell carcinoma.
- Key paperHARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer
Shares Akeso, Ivonescimab, VEGF / VEGFR, PD-1.
- PersonMu-Sheng Zeng
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
- TrialHARMONi-3
Shares Ivonescimab, Non-small-cell lung cancer.
- IdeaBlood EBV DNA screening for nasopharyngeal cancer across southern China and Southeast Asia
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.